Search Result

Isoforms Recommended:	EZH1

Results for "

EZH1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Histone Methyltransferase (10) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (11) Inflammation/Immunology (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Peptides

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145602

Tulmimetostat CPI-0209	Histone Methyltransferase	Cancer
Tulmimetostat (CPI-0209) is an orally active *EZH1/EZH2* inhibitor that targets and inhibits the *EZH2* enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies ^[1] .

HY-15555

EPZ005687 5 Publications Verification	Histone Methyltransferase	Cancer
EPZ005687 is a potent and selective inhibitor of *EZH2* with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.

HY-13803

Tazemetostat Maximum Cited Publications 59 Publications Verification EPZ-6438; E-7438	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells ^[1].

HY-109108

Valemetostat 1 Publications Verification DS-3201	Histone Methyltransferase	Cancer
Valemetostat (DS-3201), a first-in-class *EZH1/2* dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma ^[1] .

HY-109108A

Valemetostat tosylate 1 Publications Verification DS-3201 tosylate	Histone Methyltransferase	Cancer
Valemetostat (DS-3201) tosylate, a first-in-class *EZH1/2* dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma ^[1] .

HY-13803R

Tazemetostat (Standard)	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells ^[1].

HY-RS04616

EZH1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EZH1 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EZH1 Human Pre-designed siRNA Set A EZH1 Human Pre-designed siRNA Set A

HY-RS04618

Ezh1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh1 Rat Pre-designed siRNA Set A Ezh1 Rat Pre-designed siRNA Set A

HY-RS04617

Ezh1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh1 Mouse Pre-designed siRNA Set A Ezh1 Mouse Pre-designed siRNA Set A

HY-122595

EZH2-IN-1	Histone Methyltransferase	Cancer
EZH2-IN-1 (compound 3) is a selective and SAM-competitive *EZH2* and *EZH1* inhibitor with an IC₅₀s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research ^[1].

HY-117947

(R)-OR-S1	Others	Cancer
(R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.

HY-144881

(S)-HH2853	Histone Methyltransferase	Inflammation/Immunology Cancer
(S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent *EZH1/2* dual inhibitor with an IC₅₀ of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases ^[1].

HY-P2266

*SAH-EZH2*	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 ^[1].

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective *EZH2* (Histone Methyltransferase) inhibitor with an IC₅₀ of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P2266

*SAH-EZH2*	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 ^[1].

EZH1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
EZH1 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh1 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Ezh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh1 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Ezh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.